Recursion Pharmaceuticals (RXRX) Notes Payables (2020 - 2024)

Recursion Pharmaceuticals (RXRX) has 5 years of Notes Payables data on file, last reported at $55000.0 in Q1 2024.

• Quarterly Notes Payables fell 91.68% year-over-year to $55000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $55000.0 (down 91.68% YoY) and the FY2023 annual result came in at $41000.0, down 57.73% from the prior year.
• Notes Payables rose to $55000.0 in Q1 2024, from $41000.0 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $3.1 million in Q2 2021 to a low of $41000.0 in Q4 2023.
• A 5-year average of $645428.6 and a median of $96000.0 in 2022 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2022 — Notes Payables sank 97.03% — and 2023, when it jumped 631.58%.
• Tracing RXRX's Notes Payables over 5 years: stood at $1.1 million in 2020, then plunged by 91.61% to $90000.0 in 2021, then grew by 7.78% to $97000.0 in 2022, then plunged by 57.73% to $41000.0 in 2023, then soared by 34.15% to $55000.0 in 2024.
• The last three Notes Payables figures came in at $55000.0 (Q1 2024), $41000.0 (Q4 2023), and $695000.0 (Q3 2023), per Business Quant data.